Skip to main content

Table 4 Criteria weights

From: Development of multi-criteria decision analysis (MCDA) framework for off-patent pharmaceuticals – an application on improving tender decision making in Indonesia

Criterion SMART Ranking Swing weighting (see Table 3) Relative scores for swing weighting Weight of non-price criteria Draft Weights Final weights of initial MCDA
Price advantage N/A 50.0% 40.0%
Quality assurance 1 Vote 5: + 50% 51.75 31.4% 15.7% 18.8%
Equivalence with the reference (original) product 2 Vote 4: + 0% (=equal importance) 34.5 20.8% 10.4% 12.5%
Product stability and drug formulation 2 Vote 3: + 50% 34.5 20.8% 10.4% 12.5%
Reliability of drug supply 3 Vote 2: + 100% 23 14.0% 7.0% 8.4%
Real world clinical or economic outcomes such as adherence or non-drug costs 4 Vote 1: + 15% 11.5 7.0% 3.5% 4.2%
Pharmacovigilance 5 N/A 10 6.0% 3.0% 3.6%